Our medicines
We are a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. In 2023, BMS invested $9.3 billion in R&D, which included the discovery and development of new medicines.
.jpeg "Our medicines")
BMS medicines available in India
OPDYTA® (Nivolumab)
YERVOI® (Ipilimumab)
ROJUZDA® (Luspatercept)
Safety reporting of medicines
Report side effects/adverse reactions or product quality complaints (Pharmacovigilance)
/ दवाओं की सुरक्षा रिपोर्टींग
000 800 440 1165 (toll free)
Monday – Friday 9 a.m. to 5 p.m. IST
Medical information contact center
000 800 440 1165 (toll free)
Monday – Friday 9 a.m. to 5 p.m. IST
NO-IN-2400012
Expiry: 14 Nov. 2026